Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OSI-7836

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Purpose: To determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, tolerability, toxicity profile… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2006
2006
PURPOSE To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in… Expand
  • table 2
  • table 3
  • table 4
  • figure 1
  • table 5
Is this relevant?
2006
2006
4′-Thio-β-d-arabinofuranosylcytosine (OSI-7836) is a nucleoside analogue with structural similarity to gemcitabine and cytarabine… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
Purpose:To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in… Expand
  • table 2
  • table 3
  • table 4
  • figure 1
  • table 5
Is this relevant?
2004
2004
OSI-7836 (4'-thio-araC, T-araC) is a nucleoside analogue that shows efficacy against solid tumor xenograft models. We examined… Expand
Is this relevant?
2004
2004
OSI-7836 (4′-thio-β-d-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of… Expand
  • figure 2
  • figure 3
  • figure 5
  • figure 4
  • table 1
Is this relevant?
2004
2004
Proc Amer Assoc Cancer Res, Volume 45, 2004 2973 OSI-7836, a nucleoside analog in development for the treatment of solid… Expand
Is this relevant?